24 May 2016 - Janssen Pharmaceuticals today announced the U.S. FDA has approved Invokamet, a fixed-dose combination therapy of Invokana (canagliflozin) and metformin hydrochloride, for first-line treatment of adults with type 2 diabetes.

With this new approval, Invokamet may now be prescribed in adults with type 2 diabetes who are not already being treated with canagliflozin or metformin and may benefit from dual therapy.

Invokamet, the first combination of a sodium glucose co–transporter 2 (SGLT2) inhibitor and metformin available in the United States, was previously approved by the FDA in August 2014 as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes not adequately controlled by either canagliflozin or metformin, or who are already being treated with both medications separately.

For more details, go to: http://www.jnj.com/news/all/US-FDA-Expands-Indication-of-INVOKAMET-canagliflozin-metformin-HCl-to-Include-First-Line-Treatment-of-Adults-with-Type-2-Diabetes